ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

Videos

HCT in MF: Is OS Better With Upfront JAKi vs. HCT? What Are the Outcomes for Allo-HSCT With Post-Transplantation Cyclophosphamide?

By ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases FEATURING Anurag K. Singh

87 views

March 8, 2021

Comments 0

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Videos

COVID-19 Coagulopathy: What Is Virchow’s Triad? What Are the VTE Rat…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

P. Harris

16 views

COVID-19 Therapeutics: Remdesivir/Bamlanivimab/Casirivimab+Imdevimab…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

K. Konrardy

11 views

COVID-19 & Hematologic Malignancies: What Is the Mortality Estimate …

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

J. Leal

23 views

2021 Updates on Thrombosis: VTE & Recurrence, Use of DOACs in GI/GU …

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

K. Halkidis

27 views

CAR-T & Experimental Therapeutics for AML: Is Allo-SCT the Only Chan…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

T. Lin

17 views

SCT for MDS: Do Older Patients With Advanced MDS Benefit From Allo-H…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

A. Singh

122 views

HCT in MF: Is OS Better With Upfront JAKi vs. HCT? What Are the Outc…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

A. Singh

87 views

ASH Update on HCT for AML: Are We Starting to Refer AML Patients Ear…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

M. Mushtaq

51 views

Allogeneic Transplantation & AML Outcomes: What Is the Role of HSCT …

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

M. Mushtaq

12 views

ASH Update on Myelofibrosis: What Are the Outcomes After Ruxolitinib…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

A. Yacoub

129 views

ASH Update on CML Management: Does the TKI Choice Affect Survival? A…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

A. Yacoub

93 views

1L Therapy for Ph- B-ALL: What Is Blinatumomab MRD Response & RFS? I…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

K. Byrd

21 views

1L Therapy for T-ALL: What Are the AALL0434 vs. AALL1231 EFS/OS Outc…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

K. Byrd

86 views

ASH Update on Intensive Induction for AML: What Is the 5-Year Follow…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

H. Male

152 views

ASH Update on Moderate-Intensity Chemo for AML: What Are the Remissi…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

H. Male

13 views

ASH Update on MDS Management: What Are the Outcomes of Venetoclax fo…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

B. Skikne

171 views

TP53 Mutations in MDS: Is Combination of Eprenetapopt + AZA Well-Tol…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

B. Skikne

120 views

ASH Update on Higher-Risk MDS: Efficacy/Safety of Pevonedistat + Aza…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

B. Skikne

123 views